Zacks Research Issues Optimistic Estimate for TBPH Earnings

Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Investment analysts at Zacks Research increased their Q2 2026 earnings per share (EPS) estimates for shares of Theravance Biopharma in a report issued on Monday, January 13th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings per share of ($0.11) for the quarter, up from their previous forecast of ($0.12). The consensus estimate for Theravance Biopharma's current full-year earnings is ($1.09) per share.

Theravance Biopharma Trading Down 1.7 %

Shares of NASDAQ:TBPH traded down $0.15 on Thursday, reaching $8.46. 166,788 shares of the company's stock were exchanged, compared to its average volume of 161,189. Theravance Biopharma has a twelve month low of $7.44 and a twelve month high of $10.44. The company has a fifty day moving average of $9.48 and a 200-day moving average of $8.90. The company has a market capitalization of $416.21 million, a price-to-earnings ratio of -8.39 and a beta of 0.21.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.16). The business had revenue of $16.87 million for the quarter, compared to the consensus estimate of $16.11 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. During the same period in the prior year, the business posted ($0.17) earnings per share.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Quantbot Technologies LP bought a new stake in Theravance Biopharma during the third quarter worth about $60,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Theravance Biopharma by 64.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company's stock worth $76,000 after acquiring an additional 3,696 shares in the last quarter. Hsbc Holdings PLC bought a new position in Theravance Biopharma in the second quarter valued at approximately $108,000. Ballentine Partners LLC acquired a new position in Theravance Biopharma during the third quarter valued at approximately $104,000. Finally, XTX Topco Ltd acquired a new position in Theravance Biopharma during the second quarter valued at approximately $129,000. Institutional investors own 99.10% of the company's stock.

Insider Buying and Selling

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction on Monday, November 11th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the transaction, the senior vice president now directly owns 322,743 shares of the company's stock, valued at $2,904,687. The trade was a 1.22 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 6.90% of the stock is currently owned by company insiders.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.